Derma Sciences Featured on NJN News and WNET 13

Derma Sciences Featured on NJN News and WNET 13

`

PRINCETON, N.J., Feb. 18 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (NASDAQ:DSCI), a specialty medical device/pharmaceutical company focused on advanced wound care, was featured on NJN News on February 16, 2010. The segment ran during the NJN Nightly News broadcast at 6:00 pm, 7:30 pm and 11:00 pm. It also aired on WNET Channel 13 in New York City at 5:30 pm.

NJN health reporter Sara Lee Kessler reported on how the medical-grade honey known as Leptospermum honey, native to New Zealand and Australia, has been found to be an effective agent in topical wound care, especially for non-healing diabetic wounds. Kessler reported how Derma Sciences' MEDIHONEY®, globally the most prescribed medical honey-based dressing for wounds and burns, helps to kick-start stalled wounds and decrease complications associated with diabetic foot ulcers. MEDIHONEY® products are manufactured and marketed by Derma Sciences, which will close on the worldwide rights to the products in the next few days.

Wound care specialists, including those at Hunterdon Wound Healing Center in Flemington, NJ, are using MEDIHONEY® dressings and say it works well on many types of wounds. Dr. Priti Gujar, Medical Director at the Hunterdon Wound Healing Center, says this particular honey is an ideal wound dressing because of its low pH levels, ability to help remove dead tissue from the wound area and ability to stimulate new tissue growth, especially in stalled wounds. "[MEDIHONEY® has] antibacterial properties which decrease the bacteria in the wound," said Dr. Gujar on camera. The wound care center has also been successfully using MEDIHONEY® in combination with hyperbaric oxygen therapy, a common and widely prescribed advanced wound care modality.

John Rymon, a patient at Hunterdon whose wounds are being treated with MEDIHONEY® dressings, told Kessler on camera that he has seen the therapy speed up the healing in his wounds.

For those wishing to view the piece, visit http://www.njn.net/news/healthreports/. Then click on the segment titled "Medical Honey February 16." The segment will be archived on the site for one month. In addition, the segment will soon be available on http://www.youtube.com/.

About Derma Sciences, Inc.

Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. Derma also has in development DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction. DSC127, an angiotensin analog, has shown positive healing results in multiple pre-clinical animal models. One possible mode of action of the drug is the up-regulation of mesenchymal stem cells at the wound site. Derma Science expects to announce the endpoint results from this study during Q3 of 2010.

Forward-Looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the Securities and Exchange Commission.

Contact:
Derma Sciences, Inc.
Edward J. Quilty
Chairman and CEO
equilty@dermasciences.com
(609) 514- 4744

The Investor Relations Group
212-825-3210
Jason Strominger (Investor Relations)
Janet Vasquez (Media Relations)

Source: Derma Sciences, Inc.

CONTACT: Edward J. Quilty, Chairman and CEO of Derma Sciences, Inc.,
+1-609-514-4744, equilty@dermasciences.com; or Investor Relations, Jason
Strominger, or Media Relations, Janet Vasquez, both of The Investor Relations
Group, +1-212-825-3210, for Derma Sciences, Inc.

Web Site: http://www.dermasciences.com/

-------
Profile: intent